Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

Similar articles for PubMed (Select 22943458)

1.

Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009.

Zetterqvist J, Asherson P, Halldner L, Långström N, Larsson H.

Acta Psychiatr Scand. 2013 Jul;128(1):70-7. doi: 10.1111/acps.12004. Epub 2012 Sep 4.

PMID:
22943458
3.

The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.

Pottegård A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI.

Eur J Clin Pharmacol. 2013 Mar;69(3):589-98. doi: 10.1007/s00228-012-1344-0. Epub 2012 Jul 19.

PMID:
22811260
4.

The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.

McCarthy S, Wilton L, Murray ML, Hodgkins P, Asherson P, Wong IC.

BMC Pediatr. 2012 Jun 19;12:78. doi: 10.1186/1471-2431-12-78.

5.

Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.

Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A.

Ann Pharmacother. 2008 Jan;42(1):24-31. Epub 2007 Nov 27.

PMID:
18042808
6.

Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.

Christensen L, Sasané R, Hodgkins P, Harley C, Tetali S.

Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617.

PMID:
20178404
7.

Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.

Preen DB, Calver J, Sanfilippo FM, Bulsara M, Holman CD.

Aust N Z J Public Health. 2007 Apr;31(2):120-6.

PMID:
17461001
8.

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E.

Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490.

9.

Trends in the prescribing of stimulant medication for the treatment of Attention Deficit Hyperactivity Disorder in adults in New South Wales.

New South Wales Department of Health.

N S W Public Health Bull. 2004;15 Suppl 3:1-55. No abstract available.

PMID:
15448720
11.

Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.

Treceño C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, Jimeno N, Escudero A, Velasco A, Carvajal A.

Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):435-41. doi: 10.1002/pds.2348. Epub 2012 Jan 17.

PMID:
22253017
12.
13.

Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study.

Garbe E, Mikolajczyk RT, Banaschewski T, Petermann U, Petermann F, Kraut AA, Langner I.

J Child Adolesc Psychopharmacol. 2012 Dec;22(6):452-8. doi: 10.1089/cap.2012.0022.

14.

Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.

Setyawan J, Guérin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

J Med Econ. 2013 Nov;16(11):1275-89. doi: 10.3111/13696998.2013.839947. Epub 2013 Sep 19.

PMID:
24004347
15.

Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults.

McCarthy S, Asherson P, Coghill D, Hollis C, Murray M, Potts L, Sayal K, de Soysa R, Taylor E, Williams T, Wong IC.

Br J Psychiatry. 2009 Mar;194(3):273-7. doi: 10.1192/bjp.bp.107.045245.

16.

ADHD medication use, adherence, persistence and cost among Texas Medicaid children.

Barner JC, Khoza S, Oladapo A.

Curr Med Res Opin. 2011;27 Suppl 2:13-22. doi: 10.1185/03007995.2011.603303.

PMID:
21973228
17.

Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands.

Sasané R, Hodgkins P, Meijer W.

Curr Med Res Opin. 2010 Nov;26(11):2565-74. doi: 10.1185/03007995.2010.518131. Epub 2010 Sep 23.

PMID:
20863165
18.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
19.

Trends of outpatient prescription drug utilization in US children, 2002-2010.

Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D.

Pediatrics. 2012 Jul;130(1):23-31. doi: 10.1542/peds.2011-2879. Epub 2012 Jun 18.

20.

Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Palli SR, Kamble PS, Chen H, Aparasu RR.

J Child Adolesc Psychopharmacol. 2012 Apr;22(2):139-48. doi: 10.1089/cap.2011.0028. Epub 2012 Feb 24.

PMID:
22364400
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk